Actelion

This study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…

This study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…

This phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.

This program offers selexipag (Uptravi) to a single patient with Buerger's disease who has a wound that won't heal. The goal is to see if the drug can help control the disease and improve wound healing. This is not a cure, and the patient may need ongoing treatment.